Table 4.
Multiple adjusted Cox proportional hazards model for analysis of drug discontinuation of a first TNF inhibitor in different BMI categories
| Variable | HR | 95% CI | p |
|---|---|---|---|
| Obese (ref: normal BMI) | 1.01 | 0.63–1.65 | 0.95 |
| Overweight (ref: normal BMI) | 0.98 | 0.79–1.38 | 0.92 |
| Age | 1.00 | 0.98–1.01 | 0.73 |
| HLA-B27 positivity | 0.86 | 0.60–1.25 | 0.43 |
| Male sex | 0.68 | 0.49–0.96 | 0.03 |
| nr-axSpA (ref: AS) | 1.47 | 1.01–2.14 | 0.04 |
| Current smoking yes vs. no | 0.92 | 0.66–1.28 | 0.61 |
| Exercise yes vs. no | 0.82 | 0.60–1.12 | 0.21 |
| BASDAI | 1.04 | 0.96–1.13 | 0.35 |
| BASMI | 1.07 | 0.97–1.18 | 0.17 |
| Elevated CRP | 0.71 | 0.51–0.98 | 0.04 |
| Enthesitis | 0.91 | 0.64–1.30 | 0.61 |
| DMARDs | 0.56 | 0.34–0.93 | 0.02 |
| NSAIDs | 1.00 | 0.55–1.83 | 0.99 |
Analysis performed in 343 patients
AS Ankylosing Spondylitis, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASMI Bath Ankylosing Spondylitis Mobility Index, BMI body mass index, CI confidence interval, CRP C-reactive peptide, DMARDs disease-modifying antirheumatic drugs, HLA-B27 human leucocyte antigen-B27, HR hazard ratio, nr-axSpA nonradiographic axial spondyloarthritis. NSAIDs nonsteroidal anti-inflammatory drugs, ref reference, TNF tumor necrosis factor